Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01833520 · ClinicalTrials.gov registry record · Phase 1
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01833520: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01833520 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01833520, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of radium-223 dichloride that can be given to patients with osteosarcoma. Radium-223 chloride is designed to work like radiation therapy in cells that are actively making bone. It is designed to target new bone growth in and around bone cancer and may kill cancer cells.
Interventions
- DRUG Ra-223 Dichloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-10-16 |
| Est. Completion | 2020-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01833520
The ClinicalTrials.gov registry entry for NCT01833520 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ra-223 Dichloride is the first listed.
NCT01833520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01833520 about?
NCT01833520 is a clinical study titled "Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma". The goal of this clinical research study is to find the highest tolerable dose of radium-223 dichloride that can be given to patients with osteosarcoma. Radium-223 chloride is designed to work like radiation therapy in cells that are actively making bone. It is designed to target new bone growth in...
What is the current status of trial NCT01833520?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-10-16. Estimated completion is 2020-04-08.
What interventions are being tested in trial NCT01833520?
The interventions under investigation include: Ra-223 Dichloride (DRUG).
Who is sponsoring clinical trial NCT01833520?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.